Skip to main
OPRX

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx Corp is positioned for substantial growth as the shift from in-person to digital pharmaceutical interactions continues, with projected revenue growth in the high teens to low twenties while expanding margins. The company's current operational capabilities support a revenue run-rate of approximately $150 million, which indicates potential operating leverage over the next few years. Additionally, OptimizeRx has reported a significant increase in gross margin and EBITDA, showcasing its effective cost management and enhanced revenue generation from its expanded product offerings in the healthcare market.

Bears say

OptimizeRx Corp has issued a downward revision of its 2026 revenue guidance, adjusting it to a range of $109 million to $114 million, which indicates only modest growth compared to previous expectations and highlights significant near-term challenges. Revenue growth is expected to decline by approximately 10% in the first half of 2026, primarily due to large pharmaceutical clients facing pressure from the Trump Administration's "most favored nation" pricing initiative. Additionally, the company's net revenue retention (NRR) has dropped significantly, reflecting reduced spending from pharma clients, which, combined with decreased visibility and lower contracted revenue, suggests a concerning outlook for future performance.

OptimizeRx Corp (OPRX) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 7 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.